Abstract: Provided is an aluminum ion detector. The aluminum ion detector may include apple extracts having a predetermined concentration, and metal nano particles coupled to the apple extracts.

Abstract: The present invention relates to a DNA-peptide complex with a high-density functional group, a DNA-peptide-nanomaterial complex and a method for production of the same, a DNA-metal nanowire, and a method for production of the same. The DNA-peptide complex with a high-density functional group may include a DNA molecule; and a peptide containing an amino acid sequence capable of binding to the DNA molecule, wherein the peptide contains at least one functional group at a terminal thereof, wherein the peptide binds to the DNA molecule via at least one of electrostatic interaction, intercalation, and groove binding.

Abstract: Provided is a multi-negative differential resistance device. The multi-negative differential resistance device includes a first negative differential resistance device and a second negative differential resistance device connected in parallel with the first negative differential resistance device, and a peak and a valley of the first negative differential resistance device and a peak and a valley of the second negative differential resistance device are synthesized, and, thus, the multi-negative differential resistance device has two peaks and two valleys.

Abstract: A compound represented by Chemical Formula 1 according to the present invention can coordinate with metal ions to form a bidirectional or multidirectional metal-organic hybrid structure. Thus, the present invention can synthesize various ligands using amine-aldehyde condensation, and synthesize metal-organic materials using the same.

Abstract: Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines.

Abstract: This invention relates to the field of energy storage devices, and especially electrochemical energy storage devices including electrolytes comprising an ionic liquid, one or more solvents, and one or more salts of a Group 2 element. Effects on electrochemical performance of the electrolyte of each of the components of the electrolyte were systematically determined. In addition, interactions between the electrolytes and separator films were dissected to optimize electrochemical performance of coin cell batteries.

Abstract: A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.

Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).

Abstract: Processor(s) for detecting malicious software. A hardware virtual machine monitor (HVMM) operates under a host OS. Container(s) initialized with network application template(s) operate under a guest OS VM. A detection module operates under the guest OS VM includes a trigger detection module, a logging module and a container command module. The trigger detection module monitors activity on container(s) for a trigger event. The logging module writes activity report(s) in response to trigger event(s). The container command module issues command(s) in response to trigger event(s). The command(s) include a container start, stop and revert commands. A virtual machine control console operates under the host OS and starts/stops the HVMM. A container control module operates under the guest OSVM and controls container(s) in response to the command(s). The server communication module sends activity report(s) to a central collection network appliance that maintains a repository of activities for infected devices.

Abstract: Disclosed are a method and an apparatus for detecting real-time random access and multi-user using multiple sequence spreading. The method for detecting real-time random access and multi-user using multiple sequence spreading may include steps of selecting, by user equipment, one spreading sequence set from a plurality of spreading sequence sets randomly without a separate resource allocation and/or spreading sequence allocation, applying, by the user equipment, each of the plurality of spreading sequences included in the one spreading sequence set to each of the plurality of symbols included in a group, and transmitting, by the user equipment, each of the plurality of symbols spread based on each of the plurality of spreading sequences.

Abstract: Described herein are methods, formulations and kits for treating a patient with cancer with anti-VEGF antibodies and albumin-bound chemotherapeutic/anti-VEGF antibody nanoparticle complexes.

Abstract: The present disclosure relates to a pre-5th-Generation (5G) or 5G communication system to be provided for supporting higher data rates beyond 4th-Generation (4G) communication system such as Long Term Evolution (LTE). According to an embodiment of the disclosure, in a wireless communication system, a remote terminal transmits a relay request message to a target relay terminal. The remote terminal performs an IP allocation procedure with the target relay terminal. The remote terminal performs relay communication with the target relay terminal on the basis of the IP allocation procedure. The IP allocation procedure is performed using an IP address which has been used in previous relay communication with a source relay terminal.

Abstract: The present disclosure relates to methods, cells, and compositions for preparing T cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods for efficiently expanding and activating T cell populations for genetic engineering and adoptive T cell immunotherapies. Also provided are cells and compositions produced by the methods and methods of their use.

Abstract: One embodiment of the present disclosure provides a method for producing an angle-independent colloidal particles-based structure, the method having: preparing two or more types of hollow colloidal particles, wherein the types are distinguished based on a size of the hollow colloidal particles thereof, wherein the types have different particle sizes; and dispersing the at least two types of hollow colloidal particles to produce an amorphous structure, wherein the amorphous structure realizes the same color independently of an angle of an incident light thereto.

Abstract: A wireless local area network (WLAN) communication method and apparatus using multiple transmission speed partitioning and cooperative transmission are disclosed. The WLAN communication method includes transmitting, by access point to the nodes, transmission time slots, partitions and internal transmission priorities using transmission time slot information, partition information and internal transmission priority information, receiving uplink packet from one node, determining whether downlink data to be transmitted to the high speed or the low speed node is present, or not in the download queue, transmitting, if present, the downlink packet to the nodes, removing downlink data from the download queue for ACK, and transmitting, if not present, transmitting ACK to the nodes.

Abstract: A formulation, including: (a) a first medicament, wherein the first medicament includes an isothiocyanate functional compound/surfactant; and (b) a second medicament, wherein the second medicament includes an antineoplastic agent, such as a cytotoxic antineoplastic agent and/or a targeted antineoplastic agent.

Abstract: A solution for urushiol induced contact dermatitis is provided for in a topical solution. According to the invention, a method is provided for applying a composition of substances to the affected area, working the composition into the affected area, and removing the composition from the affected area. The composition comprises at least one ethoxylate in combination with a supporting agent. It is believed that this combination binds to the available urushiol receptors rendering it inactive. The affinity of the receptors for the ethoxylates also appears to cause a release of the urushiol from its epidermal bonds for bonding to the composition. An inert scrubbing agent, such as polyethylene beads, can also be included to assist in the release of the urushiol. Acetylated lanolin alcohol, EDTA, a foam stabilizer, and water can also be added to the composition without effecting performance.

Abstract: A series of solid solutions AlFe2_xMnxB2 have been synthesized by arc-melting and characterized by powder X-ray diffraction, and magnetic measurements. All the compounds adopt the parent AlFe2B2-type structure, in which infinite zigzag chains of B atoms are connected by Fe atoms into [Fe2B2] slabs that alternate with layers of Al atoms along the b axis. The parent AlFe2B2 is a ferromagnet with Tc=282 K. A systematic investigation of solid solutions AlFe2_xMnx.B2 showed a non-linear change in the structural and magnetic behavior. The ferromagnetic ordering temperature is gradually decreased as the Mn content (x) increases. The substitution of Mn for Fe offers a convenient method for the adjustment of the ferromagnetic ordering temperature of AlFe2B2.

Abstract: The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant L. acidophilus cells or a therapeutically effective amount of the isolated surface layer protein A (SlpA) or a non-naturally occurring derivative thereof. The recombinant L. acidophilus cells or SlpA isolated from L. acidophilus can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient. In an embodiment of the invention, the pharmaceutical composition is administered orally.

Abstract: The new and distinct zoysiagrass variety described herein is a Z. matrella x Z. japonica F1 hybrid named ‘KSUZ 0802’. ‘KSUZ 0802’ can be distinguished by its superior turf quality, fine-textured leaves, increased resistance to bluegrass billbug (Sphenophorus parvulus Ghyllenhaal), and cold tolerance that is comparable to zoysiagrass varieties adapted to the transition zone growing region in the U.S.